C&CAUSES & WHAT WE KNOW
Causes & What We Know/August 24, 2026/2 min read

When Type 1 Diabetes Isn't: Why Some Antibody-Negative Diagnoses May Be Misdiagnosed

A new study reveals that some people clinically diagnosed with Type 1 diabetes may actually have a different form of the disease. Genetic testing could help identify who needs different care.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

  • About 10-15% of people with a Type 1 diabetes diagnosis test negative for autoantibodies, the proteins that signal autoimmune attack on insulin-producing cells
  • Researchers estimate that at least 7.6% of these antibody-negative individuals may actually have nonautoimmune diabetes—a different condition requiring different treatment approaches
  • Autoantibody screening and genetic testing could help distinguish between autoimmune and nonautoimmune forms of diabetes in people without detectable antibodies
  • Accurate diagnosis matters because it guides which treatments are most likely to help

The Diagnostic Challenge

Type 1 diabetes is an autoimmune condition, meaning the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Doctors typically confirm Type 1 by finding autoantibodies—proteins that mark this autoimmune attack—in a person's blood.

But here's the puzzle: 10-15% of people clinically diagnosed with Type 1 diabetes don't have detectable autoantibodies. When these patients test negative, it raises an important question: do they actually have Type 1 diabetes, or could they have a different form of diabetes entirely?

What the New Research Shows

A study published in Diabetes examined genetic data to estimate how many antibody-negative patients might actually have nonautoimmune diabetes rather than Type 1. The researchers found that upwards of 7.6% of autoantibody-negative individuals fall into this category.

This means that among people clinically diagnosed with Type 1 but who lack autoantibodies, a meaningful proportion may have been misdiagnosed. They may have a genetic form of diabetes or another nonautoimmune condition that resembles Type 1 but requires different management.

Why This Matters

An accurate diagnosis is the foundation for effective care. If someone is told they have Type 1 diabetes when they actually have a nonautoimmune form, they may receive treatments designed for autoimmune diabetes that won't address their actual condition.

For people without autoantibodies, getting the right answer could change their treatment plan and improve outcomes. That's why researchers recommend that genetic testing become part of standard care alongside autoantibody screening for anyone with an unclear diabetes diagnosis.

What Happens Next

The findings suggest that autoantibody screening should be routine for anyone suspected of having Type 1 diabetes. For those who test negative for antibodies, genetic testing can help determine whether autoimmunity is truly absent or whether another diagnosis better explains their diabetes.

If you or a loved one has been diagnosed with Type 1 but have questions about whether antibody testing and genetic testing were performed, this research underscores why those tests matter for getting a complete picture.

Evidence label

Source: Diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.